Therefore, the data suggest that miR-193a-5p/ERBB2 pathway might be an important target for treating ESCC patients who are resistant to chemotherapy, radiotherapy and/or CCRT treatment. This evidence concerns the gene ERBB2 and esophageal squamous cell carcinoma.